{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:41:52Z","timestamp":1788907312849,"version":"build-2803163510"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["404256\/2021-0"],"award-info":[{"award-number":["404256\/2021-0"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["310606\/2021-7"],"award-info":[{"award-number":["310606\/2021-7"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00109-024-02481-1","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T11:03:18Z","timestamp":1725015798000},"page":"1187-1198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current treatment of Psoriasis triggered by Cytokine Storm and future immunomodulation strategies"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0384-9934","authenticated-orcid":false,"given":"Ge\u00f3rgia","family":"de Carvalho Braga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0109-5534","authenticated-orcid":false,"given":"Gabriel Rossi","family":"Francisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9263-4980","authenticated-orcid":false,"given":"Margarete Dulce","family":"Bagatini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"key":"2481_CR1","first-page":"97","volume":"93","author":"F Gr\u00e4n","year":"2020","unstructured":"Gr\u00e4n F, Kerstan A, Serfling E et al (2020) Current developments in the immunology of psoriasis. Yale J Biol Med 93:97\u2013110","journal-title":"Yale J Biol Med"},{"key":"2481_CR2","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.3390\/ijms21207488","volume":"21","author":"M Tokuyama","year":"2020","unstructured":"Tokuyama M, Mabuchi T (2020) New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci 21:7488","journal-title":"Int J Mol Sci"},{"key":"2481_CR3","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20:1475","journal-title":"Int J Mol Sci"},{"key":"2481_CR4","doi-asserted-by":"publisher","unstructured":"Ozaras R, Berk A, Ucar DH et al (2020) Covid\u201019 and exacerbation of psoriasis. Dermatol Ther 33. https:\/\/doi.org\/10.1111\/dth.13632","DOI":"10.1111\/dth.13632"},{"key":"2481_CR5","doi-asserted-by":"crossref","unstructured":"Recalcati S (2020) Cutaneous manifestations in COVID\u201019: a first perspective. J Eur Acad Dermatol Venereol 34. \nhttps:\/\/doi.org\/10.1111\/jdv.16387","DOI":"10.1111\/jdv.16387"},{"key":"2481_CR6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.jdcr.2020.10.013","volume":"6","author":"RJ Mathieu","year":"2020","unstructured":"Mathieu RJ, Cobb CBC, Telang GH et al (2020) New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019. JAAD Case Rep 6:1360\u20131362","journal-title":"JAAD Case Rep"},{"key":"2481_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jaci.2021.01.006","volume":"147","author":"MT Patrick","year":"2021","unstructured":"Patrick MT, Zhang H, Wasikowski R et al (2021) Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. J Allergy Clin Immunol 147:857-869.e7","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2481_CR8","doi-asserted-by":"publisher","first-page":"e15113","DOI":"10.1111\/dth.15113","volume":"34","author":"K Aram","year":"2021","unstructured":"Aram K, Patil A, Goldust M et al (2021) COVID-19 and exacerbation of dermatological diseases: a review of the available literature. Dermatol Ther 34(6):e15113. https:\/\/doi.org\/10.1111\/dth.15113","journal-title":"Dermatol Ther"},{"issue":"10","key":"2481_CR9","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1111\/jdv.19261","volume":"37","author":"S Skrek","year":"2023","unstructured":"Skrek S, Di Lernia V, Beauchet A et al (2023) Clinical and epidemiological features of psoriasis exacerbations in children with SARS-CoV-2 infection. J Eur Acad Dermatol Venereol 37(10):e1192\u2013e1195. https:\/\/doi.org\/10.1111\/jdv.19261","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2481_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/medicina58020144","volume":"58","author":"C Zanza","year":"2022","unstructured":"Zanza C, Romenskaya T, Manetti AC et al (2022) Cytokine storm in COVID-19: immunopathogenesis and therapy. Medicina (B Aires) 58:144","journal-title":"Medicina (B Aires)"},{"key":"2481_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41392-021-00553-z","volume":"6","author":"Z Huang","year":"2021","unstructured":"Huang Z, Xie N, Illes P et al (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6:162","journal-title":"Signal Transduct Target Ther"},{"key":"2481_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1080\/08923973.2021.1988102","volume":"43","author":"M Zarei","year":"2021","unstructured":"Zarei M, SahebiVaighan N, Ziai SA (2021) Purinergic receptor ligands: the cytokine storm attenuators, potential therapeutic agents for the treatment of COVID-19. Immunopharmacol Immunotoxicol 43:633\u2013643","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"2481_CR13","doi-asserted-by":"publisher","first-page":"108150","DOI":"10.1016\/j.intimp.2021.108150","volume":"100","author":"J Le\u00e3o Batista Sim\u00f5es","year":"2021","unstructured":"Le\u00e3o Batista Sim\u00f5es J, Fornari Basso H, CristineKosvoski G et al (2021) Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue. Int Immunopharmacol 100:108150","journal-title":"Int Immunopharmacol"},{"key":"2481_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11302-021-09814-6","volume":"18","author":"D Hasan","year":"2022","unstructured":"Hasan D, Shono A, van Kalken CK et al (2022) A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling. Purinergic Signal 18:13\u201359","journal-title":"Purinergic Signal"},{"key":"2481_CR15","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes MA, Su\u00e1rez-Fari\u00f1as M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32:227\u2013255","journal-title":"Annu Rev Immunol"},{"key":"2481_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00281-015-0539-8","volume":"38","author":"SK Mahil","year":"2016","unstructured":"Mahil SK, Capon F, Barker JN (2016) Update on psoriasis immunopathogenesis and targeted immunotherapy. Semin Immunopathol 38:11\u201327","journal-title":"Semin Immunopathol"},{"key":"2481_CR17","doi-asserted-by":"publisher","first-page":"12793","DOI":"10.3390\/ijms222312793","volume":"22","author":"R Singh","year":"2021","unstructured":"Singh R, Koppu S, Perche PO et al (2021) The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci 22:12793","journal-title":"Int J Mol Sci"},{"key":"2481_CR18","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jid.2021.02.764","volume":"141","author":"D Yan","year":"2021","unstructured":"Yan D, Gudjonsson JE, Le S et al (2021) New frontiers in psoriatic disease research, part I: genetics, environmental triggers, immunology, pathophysiology, and precision medicine. J Investig Dermatol 141:2112-2122.e3","journal-title":"J Investig Dermatol"},{"key":"2481_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A (2018) The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol 55:379\u2013390","journal-title":"Clin Rev Allergy Immunol"},{"key":"2481_CR20","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.3389\/fimmu.2019.01764","volume":"10","author":"MP Sch\u00f6n","year":"2019","unstructured":"Sch\u00f6n MP (2019) Adaptive and innate immunity in psoriasis and other inflammatory disorders. Front Immunol 10:1764. https:\/\/doi.org\/10.3389\/fimmu.2019.01764","journal-title":"Front Immunol"},{"key":"2481_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.5114\/ada.2022.119077","volume":"40","author":"M Kutwin","year":"2023","unstructured":"Kutwin M, Wo\u017aniacka A (2023) Interleukins 20 and 8 \u2013 less widely known cytokines in psoriasis. Adv Dermatol Allergol 40:194\u2013203","journal-title":"Adv Dermatol Allergol"},{"key":"2481_CR22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12016-007-0039-2","volume":"33","author":"BJ Nickoloff","year":"2007","unstructured":"Nickoloff BJ, Qin J-Z, Nestle FO (2007) Immunopathogenesis of psoriasis. Clin Rev Allergy Immunol 33:45\u201356","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"2481_CR23","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.1111\/ajd.12561","volume":"59","author":"L Han","year":"2018","unstructured":"Han L, Sugiyama H, Zhang Q et al (2018) Phenotypical analysis of ectoenzymes CD39\/CD73 and adenosine receptor 2A in CD4+ CD25high Foxp3 + regulatory T-cells in psoriasis. Australas J Dermatol 59(1):e31\u2013e38. https:\/\/doi.org\/10.1111\/ajd.12561","journal-title":"Australas J Dermatol"},{"key":"2481_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4049\/jimmunol.174.1.164","volume":"174","author":"H Sugiyama","year":"2005","unstructured":"Sugiyama H, Gyulai R, Toichi E et al (2005) Dysfunctional blood and target tissue CD4+CD25 high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J Immunol 174:164\u2013173","journal-title":"J Immunol"},{"key":"2481_CR25","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1080\/15384101.2019.1653099","volume":"18","author":"C Lanna","year":"2019","unstructured":"Lanna C, Mancini M, Gaziano R et al (2019) Skin immunity and its dysregulation in psoriasis. Cell Cycle 18:2581\u20132589","journal-title":"Cell Cycle"},{"key":"2481_CR26","first-page":"247","volume":"88","author":"ME Marina","year":"2015","unstructured":"Marina ME, Roman II, Constantin A-M et al (2015) VEGF involvement in psoriasis. Med Pharm Rep 88:247\u2013252","journal-title":"Med Pharm Rep"},{"key":"2481_CR27","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2353\/ajpath.2008.080088","volume":"173","author":"PM Elias","year":"2008","unstructured":"Elias PM, Arbiser J, Brown BE et al (2008) Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia. Am J Pathol 173:689\u2013699","journal-title":"Am J Pathol"},{"key":"2481_CR28","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4103\/idoj.IDOJ_309_17","volume":"9","author":"F Kaliyadan","year":"2018","unstructured":"Kaliyadan F (2018) The dermoscopic auspitz sign. Indian Dermatol Online J 9:290","journal-title":"Indian Dermatol Online J"},{"key":"2481_CR29","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.it.2009.07.008","volume":"30","author":"H Valdimarsson","year":"2009","unstructured":"Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL et al (2009) Psoriasis \u2013 as an autoimmune disease caused by molecular mimicry. Trends Immunol 30:494\u2013501","journal-title":"Trends Immunol"},{"key":"2481_CR30","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.3390\/microorganisms11092300","volume":"11","author":"S Alshamrani","year":"2023","unstructured":"Alshamrani S, Mashraqi MM, Alzamami A et al (2023) Mining autoimmune-disorder-linked molecular-mimicry candidates in clostridioides difficile and prospects of mimic-based vaccine design: an in silico approach. Microorganisms 11:2300","journal-title":"Microorganisms"},{"key":"2481_CR31","doi-asserted-by":"crossref","unstructured":"Shakoei S, Ghanadan A, Hamzelou S (2020) Pustular psoriasis exacerbated by COVID\u201019 in a patient with the history of psoriasis. Dermatol Ther 33. \nhttps:\/\/doi.org\/10.1111\/dth.14462","DOI":"10.1111\/dth.14462"},{"key":"2481_CR32","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ad.2022.07.014","volume":"115","author":"FZ Agharbi","year":"2024","unstructured":"Agharbi FZ, Basri G, Nejjari S et al (2024) Erythrodermic psoriasis following SARS-CoV-2 infection. Actas Dermosifiliogr 115:202\u2013203","journal-title":"Actas Dermosifiliogr"},{"key":"2481_CR33","first-page":"1","volume":"2022","author":"M Wu","year":"2022","unstructured":"Wu M, Teymour S, Ashinoff R et al (2022) Psoriasiform dermatitis in a COVID-19 patient. Case Rep Dermatol Med 2022:1\u20133","journal-title":"Case Rep Dermatol Med"},{"key":"2481_CR34","doi-asserted-by":"crossref","unstructured":"Lane JB, Stahly S, Sills A, et al (2022) Examination of cutaneous changes among patients following SARS-CoV-2 infection. Cureus. \nhttps:\/\/doi.org\/10.7759\/cureus.27052","DOI":"10.7759\/cureus.27052"},{"key":"2481_CR35","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2147\/CCID.S421394","volume":"16","author":"X Wang","year":"2023","unstructured":"Wang X, Yuan L, Qiu X et al (2023) Psoriasis and COVID-19 infection negatively impact each other: an analysis of 3581 cases. Clin Cosmet Investig Dermatol 16:1933\u20131936","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2481_CR36","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.jaad.2022.10.019","volume":"88","author":"CV Chalitsios","year":"2023","unstructured":"Chalitsios CV, Tsilidis KK, Tzoulaki I (2023) Psoriasis and COVID-19: a bidirectional Mendelian randomization study. J Am Acad Dermatol 88:893\u2013895","journal-title":"J Am Acad Dermatol"},{"key":"2481_CR37","doi-asserted-by":"crossref","unstructured":"Shah H, Busquets AC (2022) Psoriasis flares in patients With COVID-19 infection or vaccination: a case series. Cureus. \nhttps:\/\/doi.org\/10.7759\/cureus.25987","DOI":"10.7759\/cureus.25987"},{"key":"2481_CR38","doi-asserted-by":"publisher","first-page":"101783","DOI":"10.1016\/j.eclinm.2022.101783","volume":"56","author":"R Chang","year":"2023","unstructured":"Chang R, Yen-Ting Chen T, Wang S-I et al (2023) Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study. EClinicalMedicine 56:101783","journal-title":"EClinicalMedicine"},{"issue":"6","key":"2481_CR39","doi-asserted-by":"publisher","first-page":"e13858","DOI":"10.1111\/dth.13858","volume":"33","author":"\u00d6F Elmas","year":"2020","unstructured":"Elmas \u00d6F, Demirba\u015f A, Kutlu \u00d6 et al (2020) Psoriasis and COVID-19: a narrative review with treatment considerations. Dermatol Ther 33(6):e13858. https:\/\/doi.org\/10.1111\/dth.13858","journal-title":"Dermatol Ther"},{"issue":"11","key":"2481_CR40","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1002\/iid3.1063","volume":"11","author":"N Ghoreishi Amin","year":"2023","unstructured":"Ghoreishi Amin N, Khosravi S, Atefi N et al (2023) A systematic review and meta-analysis of investigating the mutual impact of COVID-19 and psoriasis: focusing on COVID-19 course in psoriasis and the opinion on biologics in this setting. Immun Inflamm Dis 11(11):e1063. https:\/\/doi.org\/10.1002\/iid3.1063","journal-title":"Immun Inflamm Dis"},{"key":"2481_CR41","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/j.jaad.2020.09.005","volume":"83","author":"DM Elston","year":"2020","unstructured":"Elston DM (2020) COVID, biologics, and psoriasis therapy. J Am Acad Dermatol 83:1577\u20131578","journal-title":"J Am Acad Dermatol"},{"key":"2481_CR42","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s12967-022-03767-z","volume":"20","author":"R Karki","year":"2022","unstructured":"Karki R, Kanneganti T-D (2022) Innate immunity, cytokine storm, and inflammatory cell death in COVID-19. J Transl Med 20:542","journal-title":"J Transl Med"},{"key":"2481_CR43","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu B, Huang S, Yin L (2021) The cytokine storm and COVID-19. J Med Virol 93:250\u2013256","journal-title":"J Med Virol"},{"key":"2481_CR44","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jinf.2020.03.037","volume":"80","author":"Q Ye","year":"2020","unstructured":"Ye Q, Wang B, Mao J (2020) The pathogenesis and treatment of the `Cytokine Storm\u2019 in COVID-19. J Infect 80:607\u2013613","journal-title":"J Infect"},{"issue":"3","key":"2481_CR45","doi-asserted-by":"publisher","first-page":"e12989","DOI":"10.1111\/sji.12989","volume":"93","author":"X Luo","year":"2021","unstructured":"Luo X, Zhu Y, Mao J et al (2021) T cell immunobiology and cytokine storm of COVID-19. Scand J Immunol 93(3):e12989. https:\/\/doi.org\/10.1111\/sji.12989","journal-title":"Scand J Immunol"},{"key":"2481_CR46","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH (2020) Cytokine Storm. N Engl J Med 383:2255\u20132273","journal-title":"N Engl J Med"},{"key":"2481_CR47","doi-asserted-by":"publisher","first-page":"459","DOI":"10.7150\/ijbs.59272","volume":"18","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Rubin L, Peng T et al (2022) Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. Int J Biol Sci 18:459\u2013472","journal-title":"Int J Biol Sci"},{"issue":"49","key":"2481_CR48","doi-asserted-by":"publisher","first-page":"eabd7114","DOI":"10.1126\/sciimmunol.abd7114","volume":"5","author":"L Kuri-Cervantes","year":"2020","unstructured":"Kuri-Cervantes L, Pampena MB, Meng W et al (2020) Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol 5(49):eabd7114. https:\/\/doi.org\/10.1126\/sciimmunol.abd7114","journal-title":"Sci Immunol"},{"key":"2481_CR49","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41577-020-0402-6","volume":"20","author":"Z Chen","year":"2020","unstructured":"Chen Z, John WE (2020) T cell responses in patients with COVID-19. Nat Rev Immunol 20:529\u2013536","journal-title":"Nat Rev Immunol"},{"issue":"48","key":"2481_CR50","doi-asserted-by":"publisher","first-page":"eabd2071","DOI":"10.1126\/sciimmunol.abd2071","volume":"5","author":"D Weiskopf","year":"2020","unstructured":"Weiskopf D, Schmitz KS, Raadsen MP et al (2020) Phenotype and kinetics of SARS-CoV-2\u2013specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol 5(48):eabd2071. https:\/\/doi.org\/10.1126\/sciimmunol.abd2071","journal-title":"Sci Immunol"},{"key":"2481_CR51","doi-asserted-by":"publisher","first-page":"e2336120","DOI":"10.1001\/jamanetworkopen.2023.36120","volume":"6","author":"SH Lim","year":"2023","unstructured":"Lim SH, Ju HJ, Han JH et al (2023) Autoimmune and autoinflammatory connective tissue disorders following COVID-19. JAMA Netw Open 6:e2336120","journal-title":"JAMA Netw Open"},{"key":"2481_CR52","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA 323:1945","journal-title":"JAMA"},{"key":"2481_CR53","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jid.2022.01.014","volume":"142","author":"PCM van de Kerkhof","year":"2022","unstructured":"van de Kerkhof PCM (2022) From empirical to pathogenesis-based treatments for psoriasis. J Investig Dermatol 142:1778\u20131785","journal-title":"J Investig Dermatol"},{"key":"2481_CR54","doi-asserted-by":"publisher","first-page":"316","DOI":"10.7150\/thno.49713","volume":"11","author":"JS Kim","year":"2021","unstructured":"Kim JS, Lee JY, Yang JW et al (2021) Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics 11:316\u2013329","journal-title":"Theranostics"},{"key":"2481_CR55","doi-asserted-by":"publisher","first-page":"108393","DOI":"10.1016\/j.clim.2020.108393","volume":"214","author":"W Zhang","year":"2020","unstructured":"Zhang W, Zhao Y, Zhang F et al (2020) The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol 214:108393","journal-title":"Clin Immunol"},{"key":"2481_CR56","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jinf.2020.06.052","volume":"81","author":"F Cantini","year":"2020","unstructured":"Cantini F, Niccoli L, Nannini C et al (2020) Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study. J Infect 81:647\u2013679","journal-title":"J Infect"},{"key":"2481_CR57","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1038\/s41591-021-01500-9","volume":"27","author":"RQ Cron","year":"2021","unstructured":"Cron RQ, Caricchio R, Chatham WW (2021) Calming the cytokine storm in COVID-19. Nat Med 27:1674\u20131675","journal-title":"Nat Med"},{"key":"2481_CR58","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-med-042921-112837","volume":"74","author":"RQ Cron","year":"2023","unstructured":"Cron RQ, Goyal G, Chatham WW (2023) Cytokine storm syndrome. Annu Rev Med 74:321\u2013337","journal-title":"Annu Rev Med"},{"key":"2481_CR59","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/jid.2011.344","volume":"132","author":"G Burnstock","year":"2012","unstructured":"Burnstock G, Knight GE, Greig AVH (2012) Purinergic signaling in healthy and diseased skin. J Investig Dermatol 132:526\u2013546","journal-title":"J Investig Dermatol"},{"key":"2481_CR60","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s10495-021-01663-3","volume":"26","author":"A Murao","year":"2021","unstructured":"Murao A, Aziz M, Wang H et al (2021) Release mechanisms of major DAMPs. Apoptosis 26:152\u2013162","journal-title":"Apoptosis"},{"issue":"5","key":"2481_CR61","doi-asserted-by":"publisher","first-page":"e359","DOI":"10.1002\/mco2.359","volume":"4","author":"Y Ai","year":"2023","unstructured":"Ai Y, Wang H, Liu L et al (2023) Purine and purinergic receptors in health and disease. MedComm (Beijing) 4(5):e359. https:\/\/doi.org\/10.1002\/mco2.359","journal-title":"MedComm (Beijing)"},{"key":"2481_CR62","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.bj.2016.09.002","volume":"39","author":"LEB Savio","year":"2016","unstructured":"Savio LEB, Coutinho-Silva R (2016) Purinergic signaling in infection and autoimmune disease. Biomed J 39:304\u2013305","journal-title":"Biomed J"},{"key":"2481_CR63","doi-asserted-by":"publisher","first-page":"9449","DOI":"10.3390\/ijms22179449","volume":"22","author":"D Ferrari","year":"2021","unstructured":"Ferrari D, Casciano F, Secchiero P et al (2021) Purinergic signaling and inflammasome activation in psoriasis pathogenesis. Int J Mol Sci 22:9449","journal-title":"Int J Mol Sci"},{"key":"2481_CR64","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jid.2016.08.001","volume":"137","author":"S Merighi","year":"2017","unstructured":"Merighi S, Borea PA, Varani K et al (2017) Deregulation of adenosine receptors in psoriatic epidermis: an option for therapeutic treatment. J Investig Dermatol 137:11\u201313","journal-title":"J Investig Dermatol"},{"key":"2481_CR65","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1124\/pr.117.014878","volume":"71","author":"L Antonioli","year":"2019","unstructured":"Antonioli L, Blandizzi C, Pacher P et al (2019) The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases. Pharmacol Rev 71:345\u2013382","journal-title":"Pharmacol Rev"},{"key":"2481_CR66","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/sj.jid.5700591","volume":"127","author":"S Pastore","year":"2007","unstructured":"Pastore S, Mascia F, Gulinelli S et al (2007) Stimulation of purinergic receptors modulates chemokine expression in human keratinocytes. J Investig Dermatol 127:660\u2013667","journal-title":"J Investig Dermatol"},{"key":"2481_CR67","doi-asserted-by":"publisher","first-page":"4324","DOI":"10.4049\/jimmunol.1202045","volume":"190","author":"ME Killeen","year":"2013","unstructured":"Killeen ME, Ferris L, Kupetsky EA et al (2013) Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J Immunol 190:4324\u20134336","journal-title":"J Immunol"},{"key":"2481_CR68","doi-asserted-by":"publisher","first-page":"109503","DOI":"10.1016\/j.neuropharm.2023.109503","volume":"230","author":"KA Jacobson","year":"2023","unstructured":"Jacobson KA, Pradhan B, Wen Z et al (2023) New paradigms in purinergic receptor ligand discovery. Neuropharmacology 230:109503","journal-title":"Neuropharmacology"},{"key":"2481_CR69","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.1111\/bph.15138","volume":"177","author":"F Di Virgilio","year":"2020","unstructured":"Di Virgilio F, Tang Y, Sarti AC et al (2020) A rationale for targeting the P2X7 receptor in Coronavirus disease 19. Br J Pharmacol 177:4990\u20134994","journal-title":"Br J Pharmacol"},{"key":"2481_CR70","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1021\/acsptsci.2c00128","volume":"5","author":"GS Whitehead","year":"2022","unstructured":"Whitehead GS, Karcz TP, Tosh DK et al (2022) Effects of purinergic receptor deletion or pharmacologic modulation on pulmonary inflammation in mice. ACS Pharmacol Transl Sci 5:973\u2013984","journal-title":"ACS Pharmacol Transl Sci"},{"key":"2481_CR71","doi-asserted-by":"publisher","first-page":"e110185","DOI":"10.1371\/journal.pone.0110185","volume":"9","author":"LC Mon\u00e7\u00e3o-Ribeiro","year":"2014","unstructured":"Mon\u00e7\u00e3o-Ribeiro LC, Faffe DS, Santana PT et al (2014) P2X7 receptor modulates inflammatory and functional pulmonary changes induced by silica. PLoS One 9:e110185","journal-title":"PLoS One"},{"key":"2481_CR72","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1164\/rccm.201003-0359OC","volume":"182","author":"N Riteau","year":"2010","unstructured":"Riteau N, Gasse P, Fauconnier L et al (2010) Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 182:774\u2013783","journal-title":"Am J Respir Crit Care Med"},{"key":"2481_CR73","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jdermsci.2020.09.008","volume":"100","author":"JY Kim","year":"2020","unstructured":"Kim JY, Lee EJ, Seong YJ et al (2020) AZD-9056, a P2X7 receptor inhibitor, suppresses ATP-induced melanogenesis. J Dermatol Sci 100:227\u2013229","journal-title":"J Dermatol Sci"},{"key":"2481_CR74","doi-asserted-by":"publisher","first-page":"7865","DOI":"10.3390\/ijms24097865","volume":"24","author":"VG Korb","year":"2023","unstructured":"Korb VG, Schultz IC, Beckenkamp LR et al (2023) a systematic review of the role of purinergic signalling pathway in the treatment of COVID-19. Int J Mol Sci 24:7865","journal-title":"Int J Mol Sci"},{"key":"2481_CR75","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00101-010-1829-0","volume":"60","author":"A Herminghaus","year":"2011","unstructured":"Herminghaus A, Wachowiak M, Wilhelm W et al (2011) Intraven\u00f6s verabreichtes Lidocain zur perioperativen Schmerztherapie. Anaesthesist 60:152\u2013160","journal-title":"Anaesthesist"},{"key":"2481_CR76","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.bj.2022.07.008","volume":"46","author":"ML Elizagaray","year":"2023","unstructured":"Elizagaray ML, Mazitelli I, Pontoriero A et al (2023) Lidocaine reinforces the anti-inflammatory action of dexamethasone on myeloid and epithelial cells activated by inflammatory cytokines or SARS-CoV-2 infection. Biomed J 46:81\u201392","journal-title":"Biomed J"},{"key":"2481_CR77","doi-asserted-by":"publisher","first-page":"684","DOI":"10.2174\/1381612824999180115103951","volume":"24","author":"T Pascart","year":"2018","unstructured":"Pascart T, Richette P (2018) Colchicine in gout: an update. Curr Pharm Des 24:684\u2013689","journal-title":"Curr Pharm Des"},{"key":"2481_CR78","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1080\/07853890.2021.1993327","volume":"54","author":"D Sanghavi","year":"2022","unstructured":"Sanghavi D, Bansal P, Kaur IP et al (2022) Impact of colchicine on mortality and morbidity in COVID-19: a systematic review. Ann Med 54:775\u2013789","journal-title":"Ann Med"},{"key":"2481_CR79","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1136\/annrheumdis-2011-143578","volume":"71","author":"EC Keystone","year":"2012","unstructured":"Keystone EC, Wang MM, Layton M et al (2012) Clinical evaluation of the efficacy of the P2X 7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis 71:1630\u20131635","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2481_CR80","first-page":"2247","volume":"21","author":"A Eser","year":"2015","unstructured":"Eser A, Colombel J-F, Rutgeerts P et al (2015) Safety and efficacy of an oral inhibitor of the purinergic receptor P2X7 in adult patients with moderately to severely active Crohn\u02bcs Disease. Inflamm Bowel Dis 21(10):2247\u20132253","journal-title":"Inflamm Bowel Dis"},{"key":"2481_CR81","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1021\/jm500324g","volume":"58","author":"J-H Park","year":"2015","unstructured":"Park J-H, Lee G-E, Lee S-D et al (2015) Discovery of Novel 2,5-dioxoimidazolidine-based P2X 7 receptor antagonists as constrained analogues of KN62. J Med Chem 58:2114\u20132134","journal-title":"J Med Chem"},{"key":"2481_CR82","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.imbio.2016.02.003","volume":"221","author":"G Corr\u00eaa","year":"2016","unstructured":"Corr\u00eaa G, de Lindenberg CA, Fernandes-Santos C et al (2016) The purinergic receptor P2X7 role in control of Dengue virus-2 infection and cytokine\/chemokine production in infected human monocytes. Immunobiology 221:794\u2013802","journal-title":"Immunobiology"},{"key":"2481_CR83","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.jhep.2017.05.021","volume":"67","author":"LEB Savio","year":"2017","unstructured":"Savio LEB, de Andrade MP, Figliuolo VR et al (2017) CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury. J Hepatol 67:716\u2013726","journal-title":"J Hepatol"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-024-02481-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-024-02481-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-024-02481-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T18:02:06Z","timestamp":1726941726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-024-02481-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2481"],"URL":"https:\/\/doi.org\/10.1007\/s00109-024-02481-1","relation":{},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"16 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"An informed consent and a consent to publish were obtained from each of the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}